ClinicalTrials.gg
CompletedNCT00283062Updated Jan 26, 2012Results posted

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

A Phase 3 interventional study of Docetaxel (TAXOTERE®) Chemotherapy and Leuprolide acetate ( ELIGARD®) Hormonal Therapy in Prostatic Neoplasms, sponsored by Sanofi. Completed at 17 sites in 17 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-26.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
30th of 185
228 · median 39
Started
2005
with 20 others
Phase 3
30 of 193
5 open now
Registered
63rd of 193
by date
Lead sponsor
11 of 193
Sanofi

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 30th largest by enrollment of the 185 interventional ones that give a count, is one of 21 that started in 2005, is one of 30 in phase 3, and was the 63rd registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, randomized phase III study in participants at high risk of recurrent prostate cancer after radical prostatectomy. The study will investigate

  • Treatment with docetaxel (TAXOTERE®) every three weeks (q3w) plus leuprolide acetate (ELIGARD®) versus leuprolide acetate alone (ELIGARD®)
  • Immediate treatment following prostatectomy versus deferred treatment at the time of relapse

Using a 2x2 factorial design participants will therefore be randomized to

  • Immediate adjuvant treatment with docetaxel plus leuprolide acetate (chemotherapy and hormonal therapy)
  • Immediate adjuvant treatment with leuprolide acetate alone (hormonal therapy)
  • Deferred treatment with docetaxel plus leuprolide acetate (chemotherapy and hormonal therapy)
  • Deferred treatment with leuprolide acetate alone (hormonal therapy)

Primary Objective:

  • The primary objective of the study is to compare progression-free survival using a 2x2 factorial design

Secondary Objectives:

  • To compare the 5-year overall, cancer-specific and metastasis-free survival after systemic treatment between the groups
  • To compare the safety and tolerability between Docetaxel in combination with leuprolide acetate and leuprolide acetate alone.
  • To evaluate quality of life as measured by the FACT-P questionnaire.

Originally, 1696 participants were planned in the study (with 424 participants randomized to each arm). However, only a total of 211 participants completed the randomization procedure as of 26 September 2007. Thus, sanofi-aventis, in accordance with the Steering Committee, decided to stop the participant recruitment as of 26 September 2007. Participants who had already signed their Informed Consent (IC) before September 26, 2007 were allowed to enter the randomization if they met eligibility criteria. The final revised number of planned participants to be randomly assigned to the 4 treatment arms was 250, and 228 participants were actually randomized.

The final sample size did not allow all the statistical analyses to be conducted on efficacy data. Therefore, the protocol was amended to reflect the change in the plans for statistical analysis. The study was underpowered to serve as the basis for drawing conclusions regarding efficacy and quality of life (QoL) endpoints.

Read the detailed description

The study consisted of the following:

  • Randomization of eligible participants within 120 days of prostatectomy
  • For participants assigned to immediate therapy, a treatment period up to 18 months within 8 days of randomization
  • For participants assigned to deferred treatment, a treatment period up to 18 months after evidence of progression prior to December 2010. Participants who did not progress before December 2010 were withdrawn from the study.
03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who met all of the following criteria were considered for enrollment into the study.

  • confirmed adenocarcinoma of the prostate based on central pathology review. All other variants are excluded
  • Randomization should occur less than 120 days after prostatectomy AND lymphadenectomy.
  • A predicted probability of 5-year freedom from progression ≤ 60%, as determined by the postoperative nomogram developed by M. Kattan.
  • Bone-scan without evidence of (within 6 months of randomization)
  • Chest x-ray without evidence of metastasis (within 6 months of randomization)
  • Abdominal computed tomography (CT) Scan without evidence of metastasis (within 6 months of randomization)
  • (ECOG) performance status ≤ 1
  • Hematology evaluation within 2 weeks prior to randomization:

    • Neutrophils ≥ 2,000/mm3
    • ≥ 10 g/dL
    • ≥ 100,000/mm3
  • Hepatic and renal function evaluation within 2 weeks prior to randomization:

    • Serum creatinine ≤1.5 × Upper normal limit (UNL) for the institution. If serum creatinine is > 1.5 × UNL, calculate (should be ≥ 60ml/minute).
    • Total serum ≤ UNL for the institution. Participants with Gilbert's syndrome may be eligible if indirect serum bilirubin levels at the time of randomization and, at least 6 month prior to randomization, confirm this condition (i.e. elevated indirect serum bilirubin).
    • Serum glutamic oxaloacetic transaminase () and/or serum glutamic pyruvic transaminase (SGPT) ≤ 1.5 × institutional UNL if alkaline phosphatase is ≤ UNL OR
    • alkaline phosphatase ≤ 5 × UNL if SGOT and SGPT are ≤ UNL
  • Prostate Specific Antigen (PSA) evaluation within 9 months prior to prostatectomy. However, a 120-day timeframe is recommended
  • Post operative PSA necessary for eligibility is defined as a level ≤ 0.2ng/mL using a standard assay at least 30 days after radical prostatectomy and within 7 days prior to randomization. Note that randomization should occur within 120 days after radical prostatectomy
  • Serum testosterone ≥ 150ng/dL within 6 months prior to randomization.

Exclusion criteria

Exclusion Criteria:

Participants presenting with any of the following will not be included in the study.

  • Prior systemic treatment for prostate cancer with hormonal therapy, chemotherapy, or any other anticancer therapy.
  • Prior radiation therapy.
  • Participants who received, are receiving or scheduled to receive post-operative radiotherapy.
  • Participants taking alternative therapies for cancer must stop taking these therapies prior to randomization. Alternative therapies are not allowed during the treatment or follow-up portions of the study. This includes (but is not limited to) alternative therapies such as :

    • PC-SPES (all types)
    • 5-alpha reductase inhibitors
  • Bisphosphonates are to be stopped prior to randomization and are not allowed during the study.
  • Chronic treatment with unless initiated > 6 months prior to study entry and at low dose ( ≤ 20 mg methylprednisolone per day or equivalent).
  • History of a other than prostate cancer. Exceptions to these criteria include:

    • participants with adequately treated non-melanoma skin cancers, and
    • participants with a history of another malignancy that was curatively treated (including participants with superficial bladder cancer) and who have not had evidence of disease for a minimum of 5 years.
  • Peripheral neuropathy ≥ Grade 2.
  • (ECG) with significant abnormalities (as determined by the investigator) within 90 days prior to randomization.
  • Participants who are medically unstable, including but not limited to active infection, acute hepatitis, gastrointestinal bleeding, uncontrolled cardiac arrhythmias, interstitial lung disease, inflammatory bowel disease, uncontrolled angina, uncontrolled hypercalcemia, uncompensated congestive heart failure, uncontrolled diabetes, dementia, seizures, superior vena cava syndrome.
  • Participants with history of to polysorbate 80.
  • Participants with a known history of viral hepatitis (B, C).

The above information was not intended to contain all considerations relevant to potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)

    Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.

    Drug: Docetaxel (TAXOTERE®) Chemotherapy · Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy

  • Active comparator
    Leuprolide Acetate - Immediate Treatment (I-HT)

    Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.

    Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy

  • Experimental
    Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)

    Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.

    Drug: Docetaxel (TAXOTERE®) Chemotherapy · Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy

  • Active comparator
    Leuprolide Acetate - Deferred Treatment (D-HT)

    Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.

    Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy

Interventions

  • 75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization. Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.

  • 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.

  • 75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed. Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.

  • 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).

  • 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression

    PFS is the interval from the date of surgery to date of progression. The date of progression was the earlier of * first PSA increase to ≥ 0.4 ng/mL confirmed within two weeks * date of the nadir, if PSA nadir did not reach \< 0.4 ng/mL (for deferred arm) * first radiological/ histological evidence of tumor progression * death. Median PFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Median PFS could not be estimated. Reported is the number of participants with disease progression.

    Time frame: from the date of surgery up to 3 years after randomization of the last participant

Secondary outcomes

  1. Median Overall Survival (OS)

    Overall survival (OS) was the time interval from the date of surgery to the date of death due to any cause. Median OS was to be estimated using Kaplan-Meier Curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Moreover, median OS could not be estimated. Reported is the number of participants who died from any cause.

    Time frame: from the date of surgery up to 3 years after randomization of the last participant

  2. Median Cancer-specific Survival (CSS)

    The CSS was the time from the date of surgery to the date of death due to prostate cancer. Median CSS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median CSS was not estimated.

    Time frame: from the date of surgery up to 3 years after randomization of the last participant

  3. Median Metastasis-free Survival (MFS)

    MFS was the interval from the date of surgery to the date of the first clinical evidence of metastasis after treatment initiation. Metastasis was evaluated by a physical exam or radiologically on bone scan or CT scan. Local (palpable) progression, documented histologically or by imaging techniques was considered evidence of progression. Median MFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median MFS was not estimated.

    Time frame: from the date of surgery up to 3 years after randomization of the last participant

  4. To Evaluate Quality of Life (QoL) as Measured Using a Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire

    The FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better QoL with fewer symptoms. A score of 156 represents the best outcome. Note: Enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn due to the low sample size.

    Time frame: from 30 days before randomization (baseline) and 18 months after treatment initiation (for change from baseline)

  5. Assessment of Safety and Tolerability - Number of Participants With Adverse Events (AE)

    Number of participants with treatment-emergent adverse events (TEAE). A TEAE was as any adverse event that occurred or worsened during the on-treatment period, which was the period from the day of first infusion of study treatment until 30 days after the last infusion of study treatment.

    Time frame: from treatment initiation up to 19 months after treatment initiation

07

Results

Posted Jan 23, 2012
Limitations and caveats
The study had difficulties in meeting enrollment goals within a reasonable time frame. The final sample size allowed for the safety analyses but was underpowered for drawing conclusions regarding efficacy and quality of life (QoL) endpoints.

Participant flow

Originally, the study was planned for 1696 participants to be randomized. However, enrollment was not met and in September 2007, the Steering Committee decided to stop recruitment. Only participants who had signed Informed Consent by then and met eligibility criteria were randomized. 228 participants were randomized to this study.

Participant flow — Overall Study
MilestoneDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
Started55555662
Administered study treatment50512017
Completed hormonal therapy (6 cycles)44481513
Completed chemotherapy (6 cycles)430150
Completed43481513
Not completed1274149
Withdrew: Did not receive any study medication543645
Withdrew: Adverse event2010
Withdrew: Lost to follow-up1010
Withdrew: Progressive disease0010
Withdrew: Participant did not wish to continue3210
Withdrew: Undefined0114
Withdrew: Chemotherapy not completed (cycle 6)1000

Outcome measures

PrimaryProgression-free Survival (PFS) Assessment - Number of Participants With Disease Progression

PFS is the interval from the date of surgery to date of progression. The date of progression was the earlier of * first PSA increase to ≥ 0.4 ng/mL confirmed within two weeks * date of the nadir, if PSA nadir did not reach \< 0.4 ng/mL (for deferred arm) * first radiological/ histological evidence of tumor progression * death. Median PFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Median PFS could not be estimated. Reported is the number of participants with disease progression.

Time frame:
from the date of surgery up to 3 years after randomization of the last participant
Reported as:
Number · participants
Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression
participantsDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression101498
SecondaryMedian Overall Survival (OS)

Overall survival (OS) was the time interval from the date of surgery to the date of death due to any cause. Median OS was to be estimated using Kaplan-Meier Curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Moreover, median OS could not be estimated. Reported is the number of participants who died from any cause.

Time frame:
from the date of surgery up to 3 years after randomization of the last participant
Reported as:
Number · participants
Median Overall Survival (OS)
participantsDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
Median Overall Survival (OS)0211
SecondaryMedian Cancer-specific Survival (CSS)

The CSS was the time from the date of surgery to the date of death due to prostate cancer. Median CSS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median CSS was not estimated.

Time frame:
from the date of surgery up to 3 years after randomization of the last participant
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryMedian Metastasis-free Survival (MFS)

MFS was the interval from the date of surgery to the date of the first clinical evidence of metastasis after treatment initiation. Metastasis was evaluated by a physical exam or radiologically on bone scan or CT scan. Local (palpable) progression, documented histologically or by imaging techniques was considered evidence of progression. Median MFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median MFS was not estimated.

Time frame:
from the date of surgery up to 3 years after randomization of the last participant
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryTo Evaluate Quality of Life (QoL) as Measured Using a Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire

The FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better QoL with fewer symptoms. A score of 156 represents the best outcome. Note: Enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn due to the low sample size.

Time frame:
from 30 days before randomization (baseline) and 18 months after treatment initiation (for change from baseline)
Reported as:
Mean · score on a scale
To Evaluate Quality of Life (QoL) as Measured Using a Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire
score on a scaleDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
Baseline124.0 ± 6.0121.5 ± 17.8114.7 ± 13.9119.7 ± 15.8
Change from Baseline (N=33, N=41, N=12, N=10)0.7 ± 12.61.7 ± 17.26.7 ± 15.96.1 ± 18.9
SecondaryAssessment of Safety and Tolerability - Number of Participants With Adverse Events (AE)

Number of participants with treatment-emergent adverse events (TEAE). A TEAE was as any adverse event that occurred or worsened during the on-treatment period, which was the period from the day of first infusion of study treatment until 30 days after the last infusion of study treatment.

Time frame:
from treatment initiation up to 19 months after treatment initiation
Reported as:
Number · participants
Assessment of Safety and Tolerability - Number of Participants With Adverse Events (AE)
participantsDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
with any adverse event (AE)47481914
with any serious adverse event (SAE)12852
with an SAE resulting in death0000
with a drug-related AE47431810
with a drug-related SAE6020
with AE leading to discontinue all study therapy2010
with AE leading to chemotherapy discontinuation1NA1NA
with AE leading to chemotherapy dose reduction5NA2NA

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)—12/50 (24%)47/50 (94%)
Leuprolide Acetate - Immediate Treatment (I-HT)—8/51 (15.7%)48/51 (94.1%)
Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)—5/20 (25%)19/20 (95%)
Leuprolide Acetate - Deferred Treatment (D-HT)—2/17 (11.8%)13/17 (76.5%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
Febrile neutropeniaBlood and lymphatic system disorders3/500/512/200/17
ArthropathyMusculoskeletal and connective tissue disorders1/500/510/201/17
Blood cholesterol increasedInvestigations0/500/510/201/17
Blood glucose increasedInvestigations0/500/510/201/17
Blood triglycerides increasedInvestigations0/500/510/201/17
ColitisGastrointestinal disorders0/500/511/200/17
DiarrhoeaGastrointestinal disorders0/500/511/200/17
PyrexiaGeneral disorders1/500/511/200/17
FatigueGeneral disorders0/500/511/200/17
Oedema peripheralGeneral disorders0/500/511/200/17
Most frequent other events
Showing 10 of 277
Most frequent other events
EventDocetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)
Hot flushVascular disorders36/5038/5111/208/17
FatigueGeneral disorders32/5016/5113/203/17
AlopeciaSkin and subcutaneous tissue disorders29/500/519/200/17
DysgeusiaNervous system disorders17/500/515/200/17
Erectile dysfunctionReproductive system and breast disorders15/5017/511/201/17
NauseaGastrointestinal disorders16/504/514/201/17
DiarrhoeaGastrointestinal disorders14/502/516/200/17
Nail disorderSkin and subcutaneous tissue disorders14/500/516/200/17
Urinary incontinenceRenal and urinary disorders15/5014/510/202/17
HeadacheNervous system disorders14/503/513/200/17

Baseline characteristics

Age Continuous
Age Continuous(years)Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)Total
Mean61.2 ± 7.461.6 ± 7.062.1 ± 762.9 ± 7.561.9 ± 7.2
Age, Customized
Age, Customized(participants)Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)Total
<65 years37343535141
>=65 years1821212787
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)Total
Female00000
Male55555662228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)Leuprolide Acetate - Immediate Treatment (I-HT)Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)Leuprolide Acetate - Deferred Treatment (D-HT)Total
White48494359199
Black637218
Asian/Oriental01405
Multiracial00202
Other12014
08

Study locations

17 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Québec, Canada
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Frankfurt, Germany
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
  • Sanofi-Aventis Administrative Office
    PE Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Gauteng, South Africa
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2006
First posted
Jan 27, 2006
Start
Dec 2005
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jan 23, 2012
Last update
Jan 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00283062
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 27, 2006
Start date
Dec 2005
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jan 23, 2012
Last update
Jan 26, 2012

Study contacts

Jean-Philippe Aussel
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion